Results 101 to 110 of about 30,927 (236)

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

open access: bronze, 2013
Betty Chang   +14 more
openalex   +1 more source

Life after ibrutinib? A new unmet need in CLL [PDF]

open access: bronze, 2015
Javier Pinilla‐Ibarz, Julio C. Chávez
openalex   +1 more source

Simulation Model of Ibrutinib for Chronic Lymphocytic Leukemia (CLL) With Prior Treatment

open access: bronze, 2014
Feng Pan   +6 more
openalex   +1 more source

Ibrutinib And Oral Ulcers [PDF]

open access: yesClinical Dermatology & Therapy, 2020
openaire   +1 more source

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103 [PDF]

open access: bronze, 2016
Chaitra S. Ujjani   +14 more
openalex   +1 more source

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

open access: bronze, 2014
Dominik Wodarz   +9 more
openalex   +1 more source

Ibrutinib is an effective treatment for B‐cell prolymphocytic leukaemia [PDF]

open access: bronze, 2016
Max J. Gordon   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy